{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:48:29Z","timestamp":1794491309613,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41386-025-02091-6","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:02:01Z","timestamp":1745280121000},"page":"895-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7407-880X","authenticated-orcid":false,"given":"Marcelo","family":"Falchi-Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1612-6703","authenticated-orcid":false,"given":"Fernanda","family":"Palhano-Fontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wie\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handersson","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynara","family":"Bolcont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0192-713X","authenticated-orcid":false,"given":"Sophie","family":"Laborde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0677-0439","authenticated-orcid":false,"given":"S\u00e9rgio","family":"Ruschi B. Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Montanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3947-577X","authenticated-orcid":false,"given":"David","family":"C. Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewerton","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Florence-Vilela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raissa","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"K. A. de Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via","family":"Arichelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rica","family":"J. Pantrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"V. Costa-Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Arthur","family":"da Cruz Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Antonio","family":"de Ara\u00fajo Costa Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando","family":"Nunes Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00edsa","family":"Dantas Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rom\u00e1ria B\u00e1rbara","family":"da Costa Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Arcoverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4887-8635","authenticated-orcid":false,"given":"Nicole","family":"Galv\u00e3o-Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-2485","authenticated-orcid":false,"given":"Draulio","family":"B. Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2091_CR1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"G Roth","year":"2018","unstructured":"Roth G. Global burden of disease collaborative network. global burden of disease study 2017 (GBD 2017) results. Seattle, United States: Institute for health metrics and evaluation (IHME), 2018. Lancet. 2018;392:1736\u201388.","journal-title":"Lancet"},{"key":"2091_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/bmj.39197.619190.80","volume":"334","author":"A Tylee","year":"2007","unstructured":"Tylee A, Walters P. Onset of action of antidepressants. BMJ. 2007;334:911\u20132.","journal-title":"BMJ"},{"key":"2091_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ph3010019","volume":"3","author":"R Machado-Vieira","year":"2010","unstructured":"Machado-Vieira R, Baumann J, Wheeler-Castillo C, Latov D, Henter ID, Salvadore G, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals. 2010;3:19\u201341.","journal-title":"Pharmaceuticals."},{"key":"2091_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","volume":"74","author":"CR Conway","year":"2017","unstructured":"Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression. JAMA Psychiatry. 2017;74:9.","journal-title":"JAMA Psychiatry"},{"key":"2091_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449\u201359.","journal-title":"Curr Psychiatry Rep."},{"key":"2091_CR6","first-page":"537","volume":"136","author":"KS Jacob","year":"2012","unstructured":"Jacob KS. Depression: a major public health problem in need of a multi-sectoral response. Indian J Med Res. 2012;136:537\u20139.","journal-title":"Indian J Med Res."},{"key":"2091_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jad.2011.12.036","volume":"140","author":"BH Hidaka","year":"2012","unstructured":"Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. J Affect Disord. 2012;140:205\u201314.","journal-title":"J Affect Disord."},{"key":"2091_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49:655\u201363.","journal-title":"Psychol Med"},{"key":"2091_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611\u201324.","journal-title":"Nat Rev Neurosci."},{"key":"2091_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al.\u00a0Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med."},{"key":"2091_CR11","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology. 2022;47:1854\u201362.","journal-title":"Neuropsychopharmacology."},{"key":"2091_CR12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl J Med. 2022;387:1637\u201348.","journal-title":"N. Engl J Med"},{"key":"2091_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/psymed.2024.0002","volume":"3","author":"M Falchi-Carvalho","year":"2024","unstructured":"Falchi-Carvalho M, Barros H, Bolcont R, Laborde S, Wie\u00dfner I, Ruschi B, Silva S, et al. The antidepressant effects of vaporized N,N-Dimethyltryptamine: an open-label pilot trial in treatment-resistant depression. Psychedelic Med. 2024;3:48\u201352. https:\/\/doi.org\/10.1089\/psymed.2024.0002","journal-title":"Psychedelic Med"},{"key":"2091_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"F Os\u00f3rio","year":"2015","unstructured":"Os\u00f3rio F, de L, Sanches RF, Macedo LR, Santos RG, dos, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr. 2015;37:13\u201320.","journal-title":"Rev Bras Psiquiatr"},{"key":"2091_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de Lima Os\u00f3rio F, Dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77\u201381.","journal-title":"J Clin Psychopharmacol"},{"key":"2091_CR16","first-page":"21","volume":"1","author":"LE Luna","year":"2011","unstructured":"Luna LE. Indigenous and mestizo use of ayahuasca: an overview. Ethnopharmacol Ayahuasca. 2011;1:21.","journal-title":"Ethnopharmacol Ayahuasca"},{"key":"2091_CR17","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1073\/pnas.1902174116","volume":"116","author":"MJ Miller","year":"2019","unstructured":"Miller MJ, Albarracin-Jordan J, Moore C, Capriles JM. Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. Proc Natl Acad Sci USA 2019;116:11207\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2091_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s002130000606","volume":"154","author":"J Riba","year":"2001","unstructured":"Riba J, Rodr\u00edguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, et al. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology. 2001;154:85\u201395.","journal-title":"Psychopharmacology."},{"key":"2091_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1017\/S0033291721002531","volume":"53","author":"I Wie\u00dfner","year":"2023","unstructured":"Wie\u00dfner I, Falchi M, Palhano-Fontes F, Feilding A, Ribeiro S, T\u00f3foli LF. LSD, madness and healing: mystical experiences as possible link between psychosis model and therapy model. Psychol Med. 2023;53:1151\u201365.","journal-title":"Psychol Med"},{"key":"2091_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F, Ley L, M\u00fcller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180\u20137.","journal-title":"Neuropsychopharmacology."},{"key":"2091_CR21","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","volume":"48","author":"L Ley","year":"2023","unstructured":"Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. 2023;48:1659\u201367.","journal-title":"Neuropsychopharmacology."},{"key":"2091_CR22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med"},{"key":"2091_CR23","doi-asserted-by":"publisher","first-page":"1485337","DOI":"10.3389\/fpsyt.2024.1485337","volume":"15","author":"C Chaves","year":"2024","unstructured":"Chaves C, Dos Santos RG, Dursun SM, Tusconi M, Carta MG, Brietzke E, et al. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics. Front Psychiatry. 2024;15:1485337.","journal-title":"Front Psychiatry"},{"key":"2091_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Gatch MB.Neuropharmacology of N,N-dimethyltryptamine.Brain Res Bull. 2016;126:74\u201388. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.04.016.","journal-title":"Brain Res Bull"},{"key":"2091_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fnins.2018.00536","volume":"12","author":"SAN Barker","year":"2018","unstructured":"Barker SAN. N-Dimethyltryptamine (DMT), an endogenous hallucinogen: past, present, and future research to determine its role and function. Front Neurosci. 2018;12:536.","journal-title":"Front Neurosci."},{"key":"2091_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.1166127","volume":"323","author":"D Fontanilla","year":"2009","unstructured":"Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323:934\u20137.","journal-title":"Science."},{"key":"2091_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/BF02157378","volume":"12","author":"S Szara","year":"1956","unstructured":"Szara S. Dimethyltryptamin: its metabolism in man; the relation to its psychotic effect to the serotonin metabolism. Experientia. 1956;12:441\u20132.","journal-title":"Experientia"},{"key":"2091_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994;51:85\u201397.","journal-title":"Arch Gen Psychiatry"},{"key":"2091_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51:98\u2013108.","journal-title":"Arch Gen Psychiatry"},{"key":"2091_CR30","first-page":"201","volume":"9","author":"S Sz\u00e1ra","year":"2007","unstructured":"Sz\u00e1ra S. DMT at fifty. Neuropsychopharmacol Hung. 2007;9:201\u20135.","journal-title":"Neuropsychopharmacol Hung."},{"key":"2091_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.euroneuro.2023.12.006","volume":"80","author":"M Falchi-Carvalho","year":"2024","unstructured":"Falchi-Carvalho M, Wie\u00dfner I, Silva SRB, Maia O, Barros L, Laborde H. S, et al. Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): a phase I clinical trial. Eur Neuropsychopharmacol. 2024;80:27\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2091_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22:603\u201320.","journal-title":"J Psychopharmacol"},{"key":"2091_CR33","doi-asserted-by":"publisher","first-page":"1133414","DOI":"10.3389\/fpsyt.2023.1133414","volume":"14","author":"JT Reckweg","year":"2023","unstructured":"Reckweg JT, van Leeuwen CJ, Henquet C, van Amelsvoort T, Theunissen EL, Mason NL, et al. A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry. 2023;14:1133414.","journal-title":"Front Psychiatry"},{"issue":"Suppl 20","key":"2091_CR34","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333.","journal-title":"J Clin Psychiatry"},{"key":"2091_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"2091_CR36","volume-title":"Psychedelic integration: psychotherapy for non-ordinary states of consciousness","author":"MB Aixal\u00e0","year":"2022","unstructured":"Aixal\u00e0 MB. Psychedelic integration: psychotherapy for non-ordinary states of consciousness. United States: Synergetic Press; 2022."},{"key":"2091_CR37","doi-asserted-by":"publisher","unstructured":"Earleywine M, Low F, Lau C, De Leo J. Integration in psychedelic-assisted treatments: recurring themes in current providers\u2019 definitions, challenges, and concerns. J Humanist Psychol. 2022. https:\/\/doi.org\/10.1177\/00221678221085800.","DOI":"10.1177\/00221678221085800"},{"key":"2091_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","volume":"238","author":"NL Galv\u00e3o-Coelho","year":"2021","unstructured":"Galv\u00e3o-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, et al. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology. 2021;238:341\u201354.","journal-title":"Psychopharmacology."},{"key":"2091_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40265-020-01303-1","volume":"80","author":"GS Malhi","year":"2020","unstructured":"Malhi GS, Morris G, Bell E, Hamilton A. A new paradigm for achieving a rapid antidepressant response. Drugs. 2020;80:755\u201364.","journal-title":"Drugs"},{"key":"2091_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. 2018;75:139\u201348.","journal-title":"JAMA Psychiatry"},{"key":"2091_CR41","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","volume":"10","author":"RJ Zeifman","year":"2019","unstructured":"Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The impact of ayahuasca on suicidality: results from a randomized controlled trial. Front Pharmacol. 2019;10:1325.","journal-title":"Front Pharmacol"},{"key":"2091_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fpsyt.2018.00185","volume":"9","author":"AC Galv\u00e3o","year":"2018","unstructured":"Galv\u00e3o AC, de M, de Almeida RN. Silva EADS, Freire FAM, Palhano-Fontes F, Onias H, et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psychiatry. 2018;9:185.","journal-title":"Front Psychiatry"},{"key":"2091_CR43","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/hbm.21381","volume":"33","author":"DB De Araujo","year":"2012","unstructured":"De Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, Pinto JP, et al. Seeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion. Hum Brain Mapp. 2012;33:2550\u201360.","journal-title":"Hum Brain Mapp"},{"key":"2091_CR44","doi-asserted-by":"publisher","first-page":"e0118143","DOI":"10.1371\/journal.pone.0118143","volume":"10","author":"F Palhano-Fontes","year":"2015","unstructured":"Palhano-Fontes F, Andrade KC, Tofoli LF, Jose ACS, Crippa AS, Hallak JEC, et al. The psychedelic state induced by Ayahuasca modulates the activity and connectivity of the Default Mode Network. PLoS ONE. 2015;10:e0118143.","journal-title":"PLoS ONE"},{"key":"2091_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02979-9","volume":"14","author":"Z Shen","year":"2024","unstructured":"Shen Z, Gao D, Lv X, Wang H, Yue W. Correction: a meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry. 2024;14:302.","journal-title":"Transl Psychiatry"},{"key":"2091_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jpsychires.2024.06.020","volume":"176","author":"EITC Lopes","year":"2024","unstructured":"Lopes EITC, Cavalcanti-Ribeiro P, Palhano-Fontes F, Gon\u00e7alves KT, da C, Nunes EA, Lima NB, de M, et al. Rapid and long-lasting effects of subcutaneous esketamine on suicidality: an open-label study in patients with treatment-resistant depression. J Psychiatr Res. 2024;176:254\u20138.","journal-title":"J Psychiatr Res"},{"key":"2091_CR47","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","volume":"369","author":"D Nutt","year":"2007","unstructured":"Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047\u201353.","journal-title":"Lancet"},{"key":"2091_CR48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1556\/2054.2022.00209","volume":"6","author":"S Kagan","year":"2022","unstructured":"Kagan S. The content of complex psychedelic experiences resulting from inhalation of N. N-dimethyltryptamine. J Psychedelic Stud. 2022;6:222\u2013231.","journal-title":"N-dimethyltryptamine. J Psychedelic Stud"},{"key":"2091_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11999-8","volume":"12","author":"DW Lawrence","year":"2022","unstructured":"Lawrence DW, Carhart-Harris R, Griffiths R, Timmermann C. Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience. Sci Rep. 2022;12:8562.","journal-title":"Sci Rep."},{"key":"2091_CR50","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 2015;29:1182\u201390.","journal-title":"J Psychopharmacol"},{"key":"2091_CR51","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.3389\/fpsyg.2018.02459","volume":"9","author":"J Barsuglia","year":"2018","unstructured":"Barsuglia J, Davis AK, Palmer R, Lancelotta R, Windham-Herman A-M, Peterson K, et al. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Front Psychol. 2018;9:2459.","journal-title":"Front Psychol"},{"key":"2091_CR52","doi-asserted-by":"publisher","first-page":"841648","DOI":"10.3389\/fphar.2022.841648","volume":"13","author":"DE-W McCulloch","year":"2022","unstructured":"McCulloch DE-W, Grzywacz MZ, Madsen MK, Jensen PS, Ozenne B, Armand S, et al. Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report. Front Pharmacol. 2022;13:841648.","journal-title":"Front Pharmacol"},{"key":"2091_CR53","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"2091_CR54","first-page":"125","volume":"24","author":"B Shanon","year":"2003","unstructured":"Shanon B. Altered states and the study of consciousness\u2014the case of ayahuasca. J Mind Behav. 2003;24:125\u201353.","journal-title":"J Mind Behav"},{"key":"2091_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1176\/appi.ajp.20230890","volume":"182","author":"JG Ramaekers","year":"2025","unstructured":"Ramaekers JG, Reckweg JT, Mason NL. Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression. Am J Psychiatry. 2025;182:33\u201346.","journal-title":"Am J Psychiatry"},{"key":"2091_CR56","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.neubiorev.2022.104793","volume":"140","author":"M van Elk","year":"2022","unstructured":"van Elk M, Yaden DB. Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neurosci Biobehav Rev. 2022;140:104793.","journal-title":"Neurosci Biobehav Rev."},{"key":"2091_CR57","first-page":"342","volume":"67","author":"JPW Burger","year":"2009","unstructured":"Burger JPW, Serne EH, Nolte F, Smulders YM. Blood pressure response to moderate physical activity is increased in obesity. Neth J Med. 2009;67:342\u20136.","journal-title":"Neth J Med."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02091-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:01:37Z","timestamp":1745582497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02091-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02091-6","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DBA has served as a scientific and clinical advisor for Biomind Labs from June 2021 to December 2022. MFC has served as the Head of the Psychiatric Research Unit at Biomind Labs Inc. from January 2022 to May 2023; both positions concluded before the start of the study on October 9, 2023, and no other relationships or activities could appear to have influenced the submitted work. The remaining authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}